Biosimilar uptake: a clinician’s perspective
Posted: 18 February 2021 | Nikki Withers (European Pharmaceutical Review) | No comments yet
To ensure that clinicians buy into biosimilars, it is important that they understand how products are analysed and compared to the originator molecules. Dr Fraser Cummings and Jonathan Sweeting discussed this issue at a recent virtual roundtable event, where they highlighted the complexities of biosimilar development pathways and approval processes. Here, Nikki Withers shares the key points raised during the live session.
Since their inception, biological medicines, or biologics, have revolutionised the treatment of many long-term medical conditions, such as rheumatoid arthritis, Crohn’s disease, psoriasis and cancer. “These medications have transformed how we care and look after patients and, more importantly, what the outcomes for patients are,” said Dr Fraser Cummings, Consultant Gastroenterologist and Honorary Associate Professor at the University Hospital Southampton NHS Foundation Trust in the UK.
Issue
Related topics
Biologics, Biopharmaceuticals, Biosimilars, Clinical Development, Drug Development, Regulation & Legislation, Therapeutics
